Cite

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).

MLA

Mitsumasa Kishimoto, et al. “Efficacy and Safety of Secukinumab in Japanese Patients with Active Ankylosing Spondylitis: 24-Week Results from an Open-Label Phase 3 Study (MEASURE 2-J).” Modern Rheumatology, vol. 30, no. 1, Jan. 2020, pp. 132–40. EBSCOhost, https://doi.org/10.1080/14397595.2018.1538004.



APA

Mitsumasa Kishimoto, Atsuo Taniguchi, Ayako Fujishige, Shuhei Kaneko, Sibylle Haemmerle, Porter, B. O., & Shigeto Kobayashi. (2020). Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Modern Rheumatology, 30(1), 132–140. https://doi.org/10.1080/14397595.2018.1538004



Chicago

Mitsumasa Kishimoto, Atsuo Taniguchi, Ayako Fujishige, Shuhei Kaneko, Sibylle Haemmerle, Brian O. Porter, and Shigeto Kobayashi. 2020. “Efficacy and Safety of Secukinumab in Japanese Patients with Active Ankylosing Spondylitis: 24-Week Results from an Open-Label Phase 3 Study (MEASURE 2-J).” Modern Rheumatology 30 (1): 132–40. doi:10.1080/14397595.2018.1538004.